In continuation to its intimation dated August 3, 2024 vide reference number ADL/SE/2024- 25/51 and February 7, 2025 vide reference number ADL/SE/2024-25/131, Aarti Drugs has informed that the Company had filed a writ petition in ‘The High Court of Judicature at Bombay’ to challenge the order passed by CGST & C.Ex. Authority. The Hon’ble Court has passed the order granting the ad-interim relief directing the CGST & C.Ex. Authority not to initiate coercive action for recovery of the amount mentiond in order passed by CGST & C.Ex. Authority. The requisite information as per Para A of Part A of Schedule III under Regulation 30 of the Listing Regulations is enclosed. The additional information pursuant to Industry Standards Note on Regulation 30 of the Listing Regulations is provided under Annexure A. The company will update the exchanges on any further updates.
The above information is a part of company’s filings submitted to BSE.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1872.40 |
| Dr. Reddys Lab | 1282.15 |
| Cipla | 1304.70 |
| Zydus Lifesciences | 956.65 |
| Lupin | 2249.70 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: